MAIN STORY
Understanding the 25% figure
According to Novo’s October 20 release, an analysis involving 2,309 female participants in REDEFINE 1 found a 25% average weight reduction after 68 weeks on CagriSema, a combination of 2.4 mg cagrilintide and 2.4 mg semaglutide, compared with 3% in the placebo group. The figure uses an efficacy estimate assuming participants remain on their assigned treatment. It does not mean that every woman lost one-quarter of her weight.
The original REDEFINE 1 trial enrolled 3,417 adults, including men and women. Across all participants, average weight reduction was 22.7% under the continued-treatment estimate and 20.4% under an approach that includes treatment discontinuation and other real-world departures from protocol. The female subgroup result therefore adds detail; it does not replace the trial’s primary result.
Why women’s life stages matter
CagriSema combines semaglutide, the GLP-1 receptor agonist used in Wegovy, with cagrilintide, an amylin analogue. The two pathways influence appetite and satiety, offering a potential treatment strategy beyond either ingredient alone.












